AbbVie stock weekly forecast: Holds gains as buyers stay in control
Shares of AbbVie Inc. (ABBV) are trading near $293 as buyers maintain control in a quiet week. The setup heading into next week focuses on whether this steady tone can hold, with key support and resistance levels likely to shape the action.
Highlights
- Shares of AbbVie closed at $292.86, slightly below last week, but remain above key long-term averages.
- Technical indicators show a mixed short-term outlook with MACD on a buy signal and Stochastic RSI in oversold territory.
- AbbVie stock is expected to fluctuate between $287.85 and $297.86 over the next five days, with a 64% probability of an increase.
Neuroscience growth and new partnerships boost sentiment and sales outlook
AbbVie's neuroscience franchise delivered 19.5% operational sales growth in the third quarter of 2026, driving the company to raise its 2026 segment sales outlook to $13 billion, according to Yahoo Finance. During the week, ABBV also expanded its pipeline by entering new AI-driven drug discovery collaborations, including extending its partnership with Brise Pharmaceuticals for migraine programs and launching a collaboration with Iambic for pipeline development. Consensus sales estimates for the current quarter point to 11% year-over-year revenue growth, as reported by Yahoo Finance.
Mixed technical signals emerge as MACD rallies and RSI nears exhaustion
On the daily chart, AbbVie is showing a firm trend with a sustained move lower, as confirmed by a volatility reading of 3.86%. Momentum signals present a mixed picture: MACD remains in strong buy territory at 5.56, but the Stochastic RSI is in the oversold zone, suggesting possible selling exhaustion and a risk of near-term rebound. Immediate support is seen at $290.45, with additional backing from the Ichimoku Kijun at $288.27, while resistance is defined by the recent high at $301. This sets the stage for potential volatility as the stock reacts to technical levels in the days ahead.
Range-bound bias expected unless support or resistance breaks next week
Over the next five trading days, AbbVie is expected to trade between $287.85 and $297.86, with a 64% probability of an increase and a 36% probability of a decrease. The base case favors further price action developing within this range as the trend consolidates. A break above resistance at $301 would open a path for additional gains, while a decisive move below the $290.45 support level could expose downside risk toward the lower end of the forecast range.
Earlier, analysts noted that AbbVie's technical setup suggested a sustained uptrend with the potential for further gains, while cautioning about possible inflection points. The current analysis adds new context with a shift to consolidation and emerging volatility, highlighting $301 as a key level that could trigger renewed upside momentum if decisively breached.